Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
As per available reports about 6 Relevant journals, 318 Conference proceedings are presently dedicated exclusively to rheumatology and about 140 Open access articles, 45 National symposiums are being published on rheumatology.
Rheumatology is a subspecialty in internal medicine, which is devoted to adequate diagnosis and therapy of rheumatic diseases. This field is multidisciplinary in nature, which means it relies on close relationships with other medical specialties. There were many advances in the recent times in the field of rheumatology, especially if we consider the development of state-of-the-art biological drugs with novel targets, made possible by rapid advances in the basic science of musculoskeletal diseases and improved imaging techniques.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Rheumatology Conference provides the scope for opportunities to learn progressed by international scientists and academicians. Rheumatology Conference offers excessive quality content to suit the diverse professional development of these medicines to treat people all over the globe. It is a perfect platform to discuss the current discoveries and developments in the field of Rheumatology. Most rheumatic diseases are treated with analgesics, NSAIDs (Non-Steroid Anti-Inflammatory Drugs), steroids (in serious cases), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), monoclonal antibodies, such as infliximab and adalimumab, and the soluble TNF receptor etanercept and Methotrexate for moderate to severe Rheumatoid arthritis. Recently, a large body of scientific research deals with the background of autoimmune disease, the cause of many rheumatic disorders. Also, the field of osteoimmunology has emerged to further examine the interactions between the immune system, joints and bones. Epidemiological studies and medication trials are also being conducted. Scientific research on biologics and clinical trials on monoclonal antibody therapies have added a new dimension to the medical treatment of arthritic disorders.
Rheumatology is a sub-speciality of internal medicine that deals with the rheumatic diseases and conditions. Rheumatology conference aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of:
1. Rheumatoid Arthritis
3. Septic arthritis
It also provides the platform for researchers, scholars and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Rheumatology.
Rheumatology is a sub-specialty in internal medicine and pediatrics, devoted to diagnosis and therapy of rheumatic diseases. Clinicians who specialize in rheumatology are called rheumatologists. Rheumatologists deal mainly with clinical problems involving joints, soft tissues, autoimmune diseases, vasculitis, and heritable connective tissue disorders. Many of these diseases are now known to be disorders of the immune system, and rheumatology is increasingly the study of immunology. Rheumatism is a colloquial term referring to any painful disorder affecting the loco-motor system including joints, muscles, connective tissues, soft tissues around the joints, and bones. This also includes rheumatic heart disease, which is specific to heart valves but has symptoms similar to rheumatic fever, which typically develops after a streptococcal infection. Rheumatologists are clinicians dealing with arthritis and other rheumatological disorders such as rheumatoid arthritis, ankylosing spondylitis, gout, and systemic lupus erythematosus. One of the major changes in modern rheumatology is the development of new drugs called biologics, or disease modifying agents, which can control severe disease more effectively.
Rheumatology is a sub speciality that deals with rheumatic diseases like rheumatoid arthritis. Rheumatoid Arthritis is an autoimmune disease that mainly attacks the synovial tissues around the joints. Out of every 100,000 people, 41 are diagnosed with Rheumatoid arthritis every year. The life time risk of developing rheumatoid arthritis is 4% in women and 3% in men. Global rheumatoid arthritis market is driven by increase in incidences of RA patients, global ageing population and increasing healthcare expenditure by government of various nations. Factors which are affecting pharmaceutical companies are pricing pressure, patent expiries of RA drugs, high costs of treatments involved and escalating R&D costs. The market is characterized by use of auto-injectors by patients for RA treatment, increase in RA cases in women and FDA approvals for RA drugs. The market for Rheumatoid arthritis therapeutics is expected to increase from $56.6 billion in 2013 to $80.7 billion in 2020, at a Compound Annual Growth Rate (CAGR) of 5.2%. The global Rheumatoid Arthritis (RA) treatment market is expected to increase in value, from $14.3 billion in 2013 to just over $19 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 4.1% according to GBI research.The market can be segmented on the basis of drugs used in rheumatology therapeutics into Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) Enbrel (etanercept). Humira (adalimumab) and Remicade (infliximab) are the major shareholders of the drugs used in rheumatology therapeutics, out of which Enbrel and Humira have the majority of the market share in the U.S. while Remicade holds its roots in the European Union. Pfizer’s Celebrex, a major drug used for the treatment of osteoarthritis, saw high sales during 2010-11 and is expected to be demanded more during the period from 2012 to 2016. The market of rheumatology therapeutics suffers restraints due to the entry of biosimilars despite healthy sales and the positive impact of the expanding geriatric population. The entry of biosimilars will slow the growth of the rheumatology therapeutics market. During the period from 2012 to 2018, the annual growth rate of the rheumatology therapeutics market is expected to fall.
4. Internal Medicine Conference
November 03-05, 2016 Baltimore, Maryland, USA
5. Healthcare Conference
October 05-07, 2015 New Delhi, India
7. Musculoskeletal Regeneration Conference
May 05-06, 2016 Chicago, USA
8. Biomaterials Conference
March 14-16, 2016 London, UK
10. Novel Physiotherapies Conference
October 20-22, 2016 Kuala Lumpur, Malaysia
16. ICOR 2016: 18th International Conference on Orthopedics and Rheumatology
March 1 - 2, 2016, Miami, USA
17. The Shoulder – Internationale Konferenz Shoulder Revision Arthroplasty 2016
January 15-16, 2016, Hambourg, Germany
18. Oswestry Intensive Course in Basic Science in Orthopaedics 2016
January 10-15, 2016, Oswestry, United Kingdom
19. Freiburger Knorpeltage 2016 – Fribourg Cartilage 2016
February 19-20, 2016, Freiburg, Germany
20. 36th Overseas Orthopaedic Meeting and 3° Indian Ocean Spine Meeting
March 26- April 02, 2016, Saint Gilles Ile de la Réunion, France.
21. Osteoarthritis Research Society International (OARSI) 2016 World Congress
March 31 - April 3, 2016 - Amsterdam, Netherlands
Relevant Society and Associations
1. National Rheumatoid Arthritis Society: NRAS
2. Indian Rheumatology Association
3. Rheumatology Nurses Society
4. Australian Rheumatology Association
5. Ontario Rheumatology Association
6. Association of Rheumatology Health Professionals
7. Taiwan Rheumatology Association
8. Canadian Rheumatology Association
9. British Society of Rheumatology
10. Rheumatology Nurses Society
11. Ontario Rheumatology Association
12. Australian Rheumatology Association
13. Pan- American League of Associations for Rheumatology
14. Florida Society for Rheumatology
15. American Arthritis Society
16. Canadian Arthritis Society
17. National Rheumatoid Arthritis Society
18. The Arthritis Society
19. American Arthritis Society
20. Brittle Bone Society
21. Bone Research Society
1. National Rheumatoid Arthritis Society: NRAS
2. rheumRx, Inc.
3. Rheumatology Center of New Jersey
4. Kennisha Rheumatology Care & Diagnostics
5. Scottsdale Rheumatology Ltd
6. British Society of Rheumatology
7. Rheumatology Nurses Society
8. Ontario Rheumatology Association
9. Australian Rheumatology Association
10. Pan- American League of Associations for Rheumatology
11. Florida Society for Rheumatology
12. Novartis International AG,
13. Novo Nordisk A/s
14. Pfizer, Inc.,
15. Teva Pharmaceutical Industries Ltd.
16. TransPharma Medical Ltd.
17. Zelos Therapeutics Inc
18. Velcura Therapeutics, Inc
19. Tornier, Inc. / LifeCell Corporation
20. Osteologix, Inc.
21. Unigene Laboratories, Inc.
This page will be updated regularly.
This page was last updated on July 12, 2020